Jaffe SA, et al. - Given the possible importance of the type of insurance as a prognostic factor in cases with hepatocellular carcinoma (HCC), as it affects access to care, researchers performed this retrospective cohort study to examine the link between insurance type at diagnosis and stage-specific survival, by utilizing data from 18 Surveillance, Epidemiology, and End Results Program cancer registries. This cohort included only people aged 20-64 years, diagnosed with primary HCC between 2010-2015, with either private, Medicaid, or no insurance. There were 14,655 cases in total. For localized, regional, and distant stage, a 43%, 22%, and 7% higher risk of death was observed, respectively, in people with Medicaid vs privately insured people with the same stage of the disease. An 88%, 59%, and 35% higher risk of death was reported for localized, regional, and distant stage, respectively, among uninsured people vs privately insured people. Overall, experts concluded that survival in people with HCC varies by insurance type at diagnosis.